1. European Urology Oncology
A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer 
Niranjan J. Sathianathen, Fernando Alarid-Escudero, Karen M. Kuntz, Nathan Lawrentschuk, Damien M. Bolton, Declan G. Murphy, Simon P. Kim, Badrinath R. Konety 
European Urology Oncology 
DOI: /j.euo
Copyright © 2019 European Association of Urology Terms and Conditions

2. Fig. 1
Cost-effectiveness acceptability curve showing the probability that a treatment represents the most cost-effective strategy at a particular willingness-to-pay threshold. QALY=quality-adjusted life year.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2019 European Association of Urology Terms and Conditions

3. Fig. 2
Incremental cost-effectiveness scatter plot of 5000 simulations demonstrating a low to moderate probability of abiraterone acetate (AA) plus androgen deprivation therapy being cost-effective even at willingness-to-pay thresholds beyond those that are commonly accepted. A point has to be to the right and below the willingness-to-pay threshold line to be cost-effective.
European Urology Oncology DOI: ( /j.euo )
Copyright © 2019 European Association of Urology Terms and Conditions